-
AHA 2024
Drugs to Target Lp(a): What’s Coming
Cardiologists Michelle O’Donoghue and Stephen Nicholls discuss the status of drugs in development that target lipoprotein (a) including recent data from the American Heart Association meeting.
Commentary, December 13, 2024
-
AHA 2024
Colchicine or MRA Post-MI: No CLEAR Benefit
Michelle O’Donoghue interviews Sanjit Jolly about his trial on routine colchicine and spironolactone post–myocardial infarction. What does it mean for MRAs and the inflammatory hypothesis?
Commentary, November 21, 2024
-
ESC 2024
Will OCEANIC-AF Sink Factor XI Inhibitors?
Cardiologists Michelle O'Donoghue and Manesh Patel discuss the disappointing findings for the factor XIa inhibitor asundexian from the OCEANIC-AF trial presented at ESC.
Commentary, September 17, 2024
-
ESC 2024
What Now for Beta-Blockers Post-MI? Reconciling REDUCE-AMI and ABYSS
Do the delayed safety concerns seen with beta-blocker discontinuation conflict with or complement REDUCE-AMI showing no benefit of early drug initiation? Drs O'Donoghue and Montalescot discuss.
Commentary, September 04, 2024
-
Threshold for Transfusion in ACS: Still Room for Discretion
Cardiologists Michelle O’Donoghue and Sunil Rao discuss more details from the MINT trial on a liberal vs conservative approach to blood transfusion in patients with anemia and acute coronary syndrome.
Experts And Viewpoints, April 22, 2024
-
A Shot in the Arm for Uncontrolled Hypertension
Cardiologists Michelle O'Donoghue and Akshay Desai discuss the results of KARDIA-2 on the siRNA drug zilebesiran in patients with uncontrolled hypertension and the potential role of renal denervation.
Experts And Viewpoints, April 15, 2024
-
Is Lifelong LDL-C Lowering Within Reach?
Michelle O'Donoghue interviews Verve CEO and cardiologist Sekar Kathiresan about PCSK9 gene editing to lower LDL cholesterol and the findings of the heart-1 study.
Experts And Viewpoints, December 11, 2023
-
PCI, the Antianginal 'Pill': ORBITA-2 in Detail
Michelle O'Donoghue interviews the sham PCI controlled trial investigators on the role of stents in the management of stable angina in light of both ORIBTA studies.
Experts And Viewpoints, November 15, 2023
-
Is It Time for Cardiologists to Treat Obesity?
Cardiologists Michelle O'Donoghue and Nicholas Marston discuss the "game changer" trial at AHA showing that GLP-1 agonist semaglutide reduced CV events in patients with ASCVD and overweight/obesity.
Experts And Viewpoints, November 13, 2023
-
Don't Fear POTS: Tips for Diagnosis and Treatment
Postural orthostatic tachycardia syndrome can challenge doctors. Cardiologists Pam Taub and Michelle O'Donoghue discuss how to diagnose and treat, and when to refer to a specialty clinic.
Experts And Viewpoints, October 09, 2023
-
Is Complete Revascularization Now Compulsory?
Michelle O'Donoghue and interventional cardiologist Sahil Parikh discuss data presented at ESC on benefits for complete revascularization in both STEMI and NSTEMI that also extend to older patients.
Experts And Viewpoints, September 08, 2023
-
Low-Dose Colchicine for ASCVD: Your Questions Answered
Cardiologist Michelle O'Donoghue asks Paul Ridker about the dos and don'ts for the anti-inflammatory drug colchicine in patients with atherosclerotic cardiovascular disease.
Experts And Viewpoints, August 08, 2023
-
The Cardiac Stress Test You Can't Ignore
Pregnancy not only reveals a woman's future CV risk but can also cause changes at the endothelial level that increase that risk. Cardiologists Michelle O'Donoghue and Rachel Bond discuss the issues.
Experts And Viewpoints, March 22, 2023
-
Is Bempedoic Acid the CLEAR Answer to Statin Intolerance?
Cardiologists Michelle O’Donoghue and Ann Marie Navar discuss the CLEAR Outcomes trial on Bempedoic acid in patients at high CV risk with statin intolerance and where this drug may fit in the lipid lowering arsenal.
Experts And Viewpoints, March 08, 2023
-
AHA 2022
Does Lipoprotein(a) Play a Causal Role in ASCVD?
Michelle L. O'Donoghue, MD, MPH, and Stephen J. Nicholls, MBBS, PhD, discuss the evidence on lipoprotein(a) and its potential role in atherosclerosis and aortic stenosis.
Experts And Viewpoints, November 28, 2022
-
AHA 2022
Did ISCHEMIA Change the Path to Cath in Stable CAD?
Michelle O'Donoghue and interventional cardiologists Rasha Al-Lamee, and Jacqueline Tamis-Holland discuss if the ISCHEMIA trial changed the management of patients with stable coronary artery disease.
Experts And Viewpoints, November 21, 2022
-
ESC 2022
What's the Best Anticoagulation Strategy for COVID-19 Patients?
Drs Michelle O'Donoghue and David Berg discuss results from the COVID-PACT study, presented at the European Society of Cardiology, on anticoagulant therapy for hospitalized patients with COVID-19.
Experts And Viewpoints, September 12, 2022
-
ESC 2022
Should Aspirin Be the Second-Line Antiplatelet in CAD?
From European Society of Cardiology 2022, Drs O'Donoghue and Valgimigli discuss the latest analysis suggesting that for single antiplatelet therapy in patients with CAD, P2Y12 inhibitors beat aspirin.
Experts And Viewpoints, August 31, 2022
-
ACC 2022
Making Healthy (Plant-Based) Diets the Easy Choice
Drs Michelle O'Donoghue and Robert Ostfeld discuss plant-based nutrition and how to make it easier for us to choose healthy foods to improve our cardiovascular health.
Experts And Viewpoints, May 09, 2022
-
ACC 2022
SuperWIN: Supermarket Partnership Improves DASH Diet Score
In a novel trial, DASH diet scores improved after participants were taught how to shop for healthier food, whether online or instore. Investigator Dylan Steen shares the details.
Experts And Viewpoints, April 06, 2022
